Prospective study of cutaneous adverse effects associated with BRAF inhibitor dabrafenib and MEK inhibitor trametinib: A study of 12 patients

被引：0
|
作者：
Lacroix, Jean-Philip [1 ]
Wang, Beatrice [2 ]
Mihalciouiu, Catalin [2 ]
机构：
[1] McGill Univ, Montreal, PQ, Canada
[2] McGill Univ, Royal Victoria Hosp, Montreal, PQ, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2016年 / 74卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
3300
引用
收藏
页码：AB68 / AB68
页数：1
相关论文
共 50 条
  • [31] Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours
    Patnaik, Amita
    Tolcher, Anthony
    Papadopoulos, Kyriakos P.
    Beeram, Murali
    Rasco, Drew
    Werner, Theresa L.
    Bauman, John W.
    Scheuber, Anita
    Cox, Donna S.
    Patel, Bela R.
    Zhou, YanYan
    Hamid, Mohammed
    Schramek, Daniel
    Sharma, Sunil
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 491 - 500
  • [32] Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).
    Bendell, Johanna C.
    Atreya, Chloe Evelyn
    Andre, Thierry
    Tabernero, Josep
    Gordon, Michael S.
    Bernards, Rene
    Van Cutsem, Eric
    Tejpar, Sabine
    Sidhu, Roger
    Go, William Y.
    Allred, Alicia
    Motwani, Monica
    Suttle, Benjamin B.
    Wu, Yuehui
    Hoos, Axel
    Orford, Keith W.
    Corcoran, Ryan Bruce
    Schellens, Jan H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma
    Anforth, R. M.
    Blumetti, T. C. M. P.
    Kefford, R. F.
    Sharma, R.
    Scolyer, R. A.
    Kossard, S.
    Long, G. V.
    Fernandez-Penas, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (05) : 1153 - 1160
  • [34] Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM)
    Schuchter, Lynn Mara
    Kudchadkar, Ragini Reiney
    Gonzalez, Rene
    Lawrence, Donald P.
    Sosman, Jeffrey Alan
    Infante, Jeffrey R.
    Daud, Adil
    Kefford, Richard
    Cebon, Jonathan S.
    Sharfman, William Howard
    Amaravadi, Ravi K.
    Boasberg, Peter D.
    Lewis, Karl D.
    Flaherty, Keith
    Ouellet, Danielle
    Little, Shonda M.
    Clark, Jennifer
    Gibney, Geoffrey Thomas
    Patel, Kiran
    Hamid, Omid
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [35] Phase II study of dabrafenib and trametinib following progression on BRAF inhibitor monotherapy in metastatic melanoma: Exploration of clinical and molecular predictors of response.
    McQuade, Jennifer Leigh
    Chen, Guo
    Panka, David J.
    Reuben, Alexandre
    Bassett, Roland L.
    Joon, Aron
    Lazar, Alexander J. F.
    Tetzlaff, Michael T.
    Simpson, Lauren
    Mouton, Rosalind
    Patel, Sapna Pradyuman
    Glitza, Isabella Claudia
    Hwu, Wen-Jen
    Amaria, Rodabe Navroze
    Diab, Adi
    Hwu, Patrick
    Wargo, Jennifer Ann
    Sullivan, Ryan J.
    Kim, Kevin
    Davies, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [36] Updated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAFi-naive metastatic melanoma
    Weber, Jeffrey S.
    Flaherty, Keith T.
    Infante, Jeffrey R.
    Falchook, Gerald Steven
    Kefford, Richard
    Daud, Adil
    Hamid, Omid
    Gonzalez, Rene
    Kudchadkar, Ragini Reiney
    Lawrence, Donald P.
    Burris, Howard A.
    Long, Georgina V.
    Algazi, Alain Patrick
    Lewis, Karl D.
    Kim, Kevin B.
    Puzanov, Igor
    Sun, Peng
    Little, Shonda M.
    Patel, Kiran
    Sosman, Jeffrey Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] A phase Ib/II study of BRAF inhibitor (BRAFi) encorafenib (ENCO) plus MEK inhibitor (MEKi) binimetinib (BINI) in cutaneous melanoma patients naive to BRAFi treatment.
    Sullivan, Ryan J.
    Weber, Jeffrey S.
    Patel, Sapna Pradyuman
    Dummer, Reinhard
    Miller, Wilson H.
    Cosgrove, David
    Carlino, Matteo S.
    Tan, Daniel Shao-Weng
    Lebbe, Celeste
    Cipani, Tiziana
    Elez, Elena
    Maacke, Heiko
    Nikolopoulos, Panagiotis
    Aout, Mounir
    De Parseval, Laure A.
    Ascierto, Paolo Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [38] BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212)
    Corcoran, Ryan Bruce
    Falchook, Gerald Steven
    Infante, Jeffrey R.
    Hamid, Omid
    Messersmith, Wells A.
    Kwak, Eunice Lee
    Ryan, David P.
    Kurzrock, Razelle
    Brenner, Adrienne A.
    Luan, Jennifer
    Sun, Peng
    Allred, Alicia J.
    Little, Shonda M.
    Patel, Kiran
    Kopetz, Scott
    Venook, Alan Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma
    Dimitriou, Florentia
    Urner-Bloch, Ursula
    Eggenschwiler, Corinne
    Mitsakakis, Nicholas
    Mangana, Joanna
    Dummer, Reinhard
    Urner, Martin
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 215 - 223
  • [40] Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma
    Daniele Ouellet
    Nastya Kassir
    Joannellyn Chiu
    Mohamad-Samer Mouksassi
    Cathrine Leonowens
    Donna Cox
    Douglas J. DeMarini
    Olivia Gardner
    Wendy Crist
    Kiran Patel
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 807 - 817
12345